CSL Behring: Targeting improvements in patient adoption and retention
CSL Behring needed an underlying platform upon which they could build and operate their current and future digital health offerings. A global biotherapeutics leader specializing in innovative therapies in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas, its aim was improving treatment experiences for patients with rare and serious diseases.
After rigorous evaluation, BrightInsight was selected, as it provides a unified platform that enables CSL Behring to develop and host digital health devices, apps, algorithms and Software as a Medical Device (SaMD) at scale while maintaining compliance with global privacy, security, quality and regulatory requirements.
In this case study, we detail how BrightInsight took CSL Behring from project kickoff to Hizentra app launch in six months. We’ll examine how the app was quickly adopted by thousands of users and earned an adoption rate of 20% of the brand’s U.S. patient population—without dedicated marketing support. We’ll show how the app is helping patients administer Hizentra, and look at data that show how the app is providing CSL with critical insights to improve patient care.
Download the case study to learn how BrightInsight took CSL Behring from project kickoff to Hizentra app launch in six months.
Digital Health Solutions to Improve Treatment Experiences for Patients with Rare Diseases Digital Health Solutions to Improve Treatment
Biopharma and R&D